By contrast, our previous cohort study found no significant increase in the risk of sight-threatening retinopathy with GLP-1 RA use compared with non-use, and in fact demonstrated a significantly lower risk compared with DPP-4 inhibitor use [27]. The gene discussed is GLP1R; the disease is retinal disorder.